

EDIT IMPLEMENTATION SCHEDULE

Clinical edits are designed to enhance patient care and optimize the use of program funds through the therapeutically prudent use of pharmaceuticals. Point-of-service pharmacy claims will be routed through an automated computer system to apply edits specifically designed to assure effective drug utilization. The edits are based on evidence-based clinical criteria and available nationally recognized peer-reviewed information. Through the clinical edit process, therapy will automatically and transparently be approved for those patients who meet any of the system approval criteria. For those participants who do not meet the system approval criteria, therapy will require a call to the MO HealthNet Drug Prior Authorization hotline at **(800) 392-8030** to initiate a review and potentially authorize claims. MO HealthNet will use the clinical edit program software to implement a state specific Preferred Drug List (PDL).

Scheduled Therapeutic Class/Drug Product Edits	Effective Date
ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations PDL Edit (Annual)	01/12/2023
ACE-Inhibitors/Calcium Channel Blocker Combinations PDL Edit (Annual)	01/12/2023
ADHD, Amphetamines, Long-Acting PDL Edit (Annual)	01/12/2023
ADHD, Amphetamines, Short-Acting PDL Edit (Annual)	01/12/2023
ADHD, Methylphenidate, Long-Acting PDL Edit (Annual)	01/12/2023
ADHD, Methylphenidate, Short-Acting PDL Edit (Annual)	01/12/2023
ADHD, Non-Stimulants PDL Edit (Annual)	01/12/2023
Alpelisib Clinical Edit (NEW)	01/12/2023
Alpha-Glucosidase Inhibitors PDL Edit (Annual)	01/12/2023
Amylin Analogs PDL Edit (Annual)	01/12/2023
Antibiotics, GI Oral PDL Edit (Annual)	01/12/2023
Antibiotics, Mupirocin Topical PDL Edit (Annual)	01/12/2023
Antibiotics, Vaginal PDL Edit (Annual)	01/12/2023
Anticoagulants PDL Edit (Annual)	01/12/2023
Anticonvulsants, Rescue Agents PDL Edit (Annual)	01/12/2023
Antihyperuricemic Agents PDL Edit (Annual)	01/12/2023
Antiplatelets PDL Edit (Annual)	01/12/2023
ARBs and ARBs/Diuretic Combinations PDL Edit (Annual)	01/12/2023
ARBs/ Calcium Channel Blocker Combinations PDL Edit (Annual)	01/12/2023
Benign Prostatic Hyperplasia (BPH) Agents PDL Edit (Annual)	01/12/2023
Beta Blockers & Beta Blockers/Diuretic Combinations PDL Edit (Annual)	01/12/2023
Biguanides & Combinations PDL Edit (Annual)	01/12/2023
Bile Salt Agents PDL Edit (Annual)	01/12/2023
Bone Ossification Agents PDL Edit (Annual)	01/12/2023
Calcium Channel Blockers, Dihydropyridines PDL Edit (Annual)	01/12/2023
Calcium Channel Blockers, Non-Dihydropyridines PDL Edit (Annual)	01/12/2023
Cephalosporin Agents PDL Edit (Annual)	01/12/2023
Colony Stimulating Factors PDL Edit (Annual)	01/12/2023
Cyproyin-Associated Periodic Syndrome (CAPS) Agents PDL Edit (Annual)	01/12/2023
Direct Renin Inhibitors & Combinations PDL Edit (Annual)	01/12/2023
DPP-IV Inhibitors & Combinations PDL Edit (Annual)	01/12/2023
Dry Eye Disease Agents PDL Edit (Annual)	01/12/2023
Electrolyte Depleting Agents, Phosphate Lowering PDL Edit (Annual)	01/12/2023
Electrolyte Depleting Agents, Potassium Lowering PDL Edit (Annual)	01/12/2023
Entresto Clinical Edit (Annual)	01/12/2023
Erythropoiesis Stimulating Agents PDL Edit (Annual)	01/12/2023
Fluoroquinolone Agents, Oral PDL Edit (Annual)	01/12/2023
Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit (Annual)	01/12/2023
Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit (Annual)	01/12/2023
Growth Hormone Agents, Somatropin PDL Edit (Annual)	01/12/2023

Scheduled Therapeutic Class/Drug Product Edits	Effective Date
Homozygous Familial Hypercholesterolemia (HoFH) Agents PDL Edit (Annual)	01/12/2023
Insulin, Long Acting PDL Edit (Annual)	01/12/2023
Insulin, Mixed PDL Edit (Annual)	01/12/2023
Insulin, Non-Analogs PDL Edit (Annual)	01/12/2023
Insulin, Rapid Acting PDL Edit (Annual)	01/12/2023
Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit (Annual)	01/12/2023
Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Edit (Annual)	01/12/2023
Macrolides PDL Edit (Annual)	01/12/2023
Meglitinides PDL Edit (Annual)	01/12/2023
Methotrexate Agents PDL Edit (Annual)	01/12/2023
Multiple Sclerosis Agents, Injectable PDL Edit (Annual)	01/12/2023
Multiple Sclerosis Agents, Oral PDL Edit (Annual)	01/12/2023
Niacin Derivatives PDL Edit (Annual)	01/12/2023
Penicillin Agents PDL Edit (Annual)	01/12/2023
Protein Convertase Subtilisin Kexin type 9 (PCSK9) Binders PDL Edit (Annual)	01/12/2023
Proton Pump Inhibitors PDL Edit (Annual)	01/12/2023
Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRAAs) PDL Edit (Annual)	01/12/2023
Pulmonary Arterial Hypertension (PAH) Agents, PDE5-Inhibitors and SGC Stimulators PDL Edit (Annual)	01/12/2023
Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Inhaled PDL Edit (Annual)	01/12/2023
Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Injectable PDL Edit (Annual)	01/12/2023
Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Oral PDL Edit (Annual)	01/12/2023
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Edit (Annual)	01/12/2023
Spinal Muscular Atrophy (SMA) Clinical Edit (Annual)	01/12/2023
Statins (HMG Co-A Reductase Inhibitors) & Combinations PDL Edit (Annual)	01/12/2023
Sulfonylureas, Second Generation PDL Edit (Annual)	01/12/2023
Sympatholytic Agents PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, IL6 Receptor Inhibitors PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, Select Agents PDL Edit (Annual)	01/12/2023
Targeted Immune Modulators, TNF Inhibitors PDL Edit (Annual)	01/12/2023
Tetracycline Agents PDL Edit (Annual)	01/12/2023
Thiazolidinediones & Combinations PDL Edit (Annual)	01/12/2023
Thrombocytopenia Agents PDL Edit (Annual)	01/12/2023
Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit (Annual)	01/12/2023
Triglyceride Lowering Agents PDL Edit (Annual)	01/12/2023
Urinary Tract Antispasmodics PDL Edit (Annual)	01/12/2023
Ampyra Clinical Edit (Annual)	10/20/2022
Besremi Clinical Edit (NEW)	10/20/2022
Botulinum Toxin Clinical Edit (Annual)	10/20/2022
CAR-T Cell Therapy Clinical Edit (Annual)	10/20/2022
Crysvita Clinical Edit (Annual)	10/20/2022
Duchenne Muscular Dystrophy (DMD) Clinical Edit (Annual)	10/20/2022
Emsam Clinical Edit (Annual)	10/20/2022
Enjaymo Clinical Edit (NEW)	10/20/2022

Scheduled Therapeutic Class/Drug Product Edits	Effective Date
Enzyme Deficiency, Select Agents Clinical Edit (NEW)	10/20/2022
Gamifant Clinical Edit (Annual)	10/20/2022
Immunoglobulins (IVIG and SCIG) Clinical Edit (Annual)	10/20/2022
Iron – Injectable Step Therapy Edit (Annual)	10/20/2022
Koselugo Clinical Edit (Annual)	10/20/2022
Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit (Annual)	10/20/2022
Luxturna Clinical Edit (Annual)	10/20/2022
Manufacturers Requiring Prior Authorization Fiscal Edit (NEW)	10/20/2022
Narcolepsy Inhibitors Clinical Edit (Annual)	10/20/2022
Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit (Annual)	10/20/2022
Nuedexta Clinical Edit (Annual)	10/20/2022
Oxandrin Clinical Edit (Annual)	10/20/2022
Palforzia Clinical Edit (NEW)	10/20/2022
Palynziq Clinical Edit (Annual)	10/20/2022
Parathyroid Hormone & Bone Resorption Suppression Related Agents Clinical Edit (Annual)	10/20/2022
Psychotropic Medications Polypharmacy Clinical Edit (Annual)	10/20/2022
Ranexa Clinical Edit (Annual)	10/20/2022
Reblozyl Clinical Edit (Annual)	10/20/2022
Selective Serotonin Reuptake Inhibitors (SSRI) Step Therapy Edit (Annual)	10/20/2022
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit (Annual)	10/20/2022
Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit (NEW)	10/20/2022
Tepezza Clinical Edit (Annual)	10/20/2022
Tolvaptan Clinical Edit (Annual)	10/20/2022
Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit (Annual)	10/20/2022
Vyvgart Clinical Edit (NEW)	10/20/2022
Xcopri Clinical Edit (Annual)	10/20/2022
Zometa Clinical Edit (Annual)	10/20/2022
Synagis Clinical Edit (Annual)	10/06/2022
Short Acting Beta Adrenergic (SABA) Agents – Inhalers Excessive Therapy Clinical Edit	08/18/2022
Short Acting Beta Adrenergic (SABA) Agents – Nebulized Excessive Therapy Clinical Edit	08/18/2022
C5 Complement Inhibitors Clinical Edit (NEW)	08/04/2022
Fabry Disease Clinical Edit (Annual)	08/04/2022
Givlaari Clinical Edit (Annual)	08/04/2022
Imcivree Clinical Edit (Annual)	08/04/2022
Isturisa Clinical Edit (Annual)	08/04/2022
Nulibry Clinical Edit (Annual)	08/04/2022
Oxervate Clinical Edit (Annual)	08/04/2022
Oxlumo Clinical Edit (Annual)	08/04/2022
Scenesse Clinical Edit (NEW)	08/04/2022
Systemic Antifungals Clinical Edit (Annual)	08/04/2022
Tavneos Clinical Edit (NEW)	08/04/2022
Voxzogo Clinical Edit (NEW)	08/04/2022
Zokinvy Clinical Edit (Annual)	08/04/2022
Acne & Rosacea – Select Topical Agents Step Therapy Edit (Annual)	07/28/2022
Sickle Cell Disease Clinical Edit (Annual)	07/28/2022
Zulresso Clinical Edit (Annual)	07/28/2022
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit (Annual)	07/21/2022
Megestrol Acetate Clinical Edit (Annual)	07/21/2022
Spravato Clinical Edit (Annual)	07/21/2022
Actinic Keratosis Agents, Topical PDL Edit (Annual)	07/07/2022

Scheduled Therapeutic Class/Drug Product Edits	Effective Date
Androgenic Agents PDL Edit (Annual)	07/07/2022
Antibiotics, Inhaled PDL Edit PDL Edit (Annual)	07/07/2022
Anticholinergics, LABA Combinations PDL Edit (Annual)	07/07/2022
Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors PDL Edit (Annual)	07/07/2022
Anticholinergics, Long Acting Inhaled PDL Edit (Annual)	07/07/2022
Anticholinergics, Short Acting and Combinations Inhaled PDL Edit (Annual)	07/07/2022
Antifungals, Oral PDL Edit (Annual)	07/07/2022
Antifungals, Topical PDL Edit (Annual)	07/07/2022
Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation PDL Edit (Annual)	07/07/2022
Antihistamines, Intranasal PDL Edit (Annual)	07/07/2022
Antihistamines, Ophthalmic PDL Edit (Annual)	07/07/2022
Antiparasitics, Topical PDL Edit (Annual)	07/07/2022
Antivirals, Herpes Oral PDL Edit (Annual)	07/07/2022
Antivirals, Topical PDL Edit (Annual)	07/07/2022
Atopic Dermatitis Agents, Immunomodulators PDL Edit (Annual)	07/07/2022
Benzoyl Peroxide/Antibiotic Combinations PDL Edit (Annual)	07/07/2022
Beta Adrenergic Agents, Long Acting PDL Edit (Annual)	07/07/2022
Beta Adrenergic Agents, Nebulized PDL Edit (Annual)	07/07/2022
Beta Adrenergic Agents, Short Acting PDL Edit (Annual)	07/07/2022
Corticosteroids and Rhinitis Agents, Intranasal PDL Edit (Annual)	07/07/2022
Corticosteroids, Ophthalmic Soft PDL Edit (Annual)	07/07/2022
Corticosteroids, Oral Inhaled PDL Edit (Annual)	07/07/2022
Corticosteroids, Topical PDL Edit (Annual)	07/07/2022
Cough/Cold Preparations PDL Edit (Annual)	07/07/2022
Epinephrine Agents, Self-Injectable PDL Edit (Annual)	07/07/2022
Fluoroquinolones, Ophthalmic PDL Edit (Annual)	07/07/2022
Fluoroquinolones, Otic PDL Edit (Annual)	07/07/2022
Glaucoma Agents PDL Edit (Annual)	07/07/2022
Hepatitis C Agents PDL Edit (Annual)	07/07/2022
Leukotriene Receptor Modifiers PDL Edit (Annual)	07/07/2022
Mast Cell Stabilizers, Ophthalmic PDL Edit (Annual)	07/07/2022
NSAIDs, Ophthalmic PDL Edit (Annual)	07/07/2022
Pancreatic Enzymes PDL Edit (Annual)	07/07/2022
Psoriasis Agents, Oral PDL Edit (Annual)	07/07/2022
Psoriasis Agents, Topical PDL Edit (Annual)	07/07/2022
Respiratory Monoclonal Antibodies (RMA) PDL Edit (Annual)	07/07/2022
Retinoids, Topical PDL Edit (Annual)	07/07/2022
Ulcerative Colitis Agents, Oral PDL Edit (Annual)	07/07/2022
Ulcerative Colitis Agents, Rectal PDL Edit (Annual)	07/07/2022
15 Day Supply – Oral Oncology Fiscal Edit (Annual)	05/19/2022
15 Day Supply Fiscal Edit (Annual)	05/19/2022
Biosimilar vs Reference Products Fiscal Edit (Annual)	05/19/2022
Diabetic Supply Quantity Limit Fiscal Edit (Annual)	05/12/2022
Extended Supply Fiscal Edit (Annual)	05/12/2022
High Cost Medications Fiscal Edit (Annual)	05/12/2022
Acetaminophen Cumulative Dose Clinical Edit (Annual)	05/05/2022
Non-Oral Contraceptives Fiscal Edit (Annual)	05/05/2022
Out-of-State, Non-Bordering Pharmacies Fiscal Edit (Annual)	05/05/2022
Selzentry Clinical Edit (Annual)	05/05/2022
BiDil Clinical Edit (Annual)	04/28/2022
Corlanor Clinical Edit (Annual)	04/28/2022
Kerendia Clinical Edit (NEW)	04/28/2022
Benzodiazepines (Select Oral) Clinical Edit (Annual)	04/28/2022

Scheduled Therapeutic Class/Drug Product Edits	Effective Date
Butalbital Combinations Excessive Therapy Edit (Annual)	04/21/2022
Butalbital Combinations without Codeine Clinical Edit (Annual)	04/21/2022
Empaveli Clinical Edit (NEW)	04/21/2022
Pompe Disease Clinical Edit (NEW)	04/21/2022
Spinal Muscular Atrophy (SMA) Clinical Edit (Annual)	04/21/2022
Antipsychotics – 1 st Generation (Typical) Clinical Edit (Annual)	04/07/2022
Antipsychotics – 2 nd Generation (Atypical) Clinical Edit and Reference List (Annual)	04/07/2022
High Risk Therapies Clinical Edit (Annual)	04/07/2022
Morphine Milligram Equivalent Accumulation Clinical Edit (Annual)	04/07/2022
Opioids – Short-Acting Clinical Edit (Annual)	04/07/2022
Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit (Annual)	04/07/2022
Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists PDL Edit (Annual)	04/07/2022
Antiandrogenic Agents PDL Edit (Annual)	04/07/2022
Anticonvulsants, Dravet Syndrome PDL Edit (Annual)	04/07/2022
Antiemetics, 5-HT ₃ and NK1 Injectables PDL Edit (Annual)	04/07/2022
Antiemetics, 5-HT ₃ , NK1 and Other Select Non-Injectables PDL Edit (Annual)	04/07/2022
Antiemetics, THC Derivatives PDL Edit (Annual)	04/07/2022
Anti-Migraine, Alternative Oral Agents PDL Edit (Annual)	04/07/2022
Anti-Migraine, Serotonin (5-HT ₁) Receptor Agonists PDL Edit (Annual)	04/07/2022
Anti-Parkinsonism, MAO-B Inhibitors PDL Edit (Annual)	04/07/2022
Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit (Annual)	04/07/2022
Antiretroviral Therapy (ART) PDL Edit (NEW)	04/07/2022
Bile Salt Agents PDL Edit (Annual)	04/07/2022
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit (Annual)	04/07/2022
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit (Annual)	04/07/2022
Fibromyalgia Agents PDL Edit (Annual)	04/07/2022
GI Motility Agents, Chronic PDL Edit (Annual)	04/07/2022
Glucagon Agents PDL Edit (Annual)	04/07/2022
Hereditary Angioedema Agents PDL Edit (Annual)	04/07/2022
Homozygous Familial Hypercholesterolemia (HoFH) PDL Edit (Annual)	04/07/2022
Neuropathic Pain Agents PDL Edit (Annual)	04/07/2022
NSAIDs PDL Edit (Annual)	04/07/2022
Opioid Dependence Agents PDL Edit (Annual)	04/07/2022
Opioid Emergency Reversal Agents PDL Edit (Annual)	04/07/2022
Opioids, Long Acting PDL Edit (Annual)	04/07/2022
Sedative Hypnotics PDL Edit (Annual)	04/07/2022
Skeletal Muscle Relaxants PDL Edit (Annual)	04/07/2022
Somatostatin Analogs PDL Edit (Annual)	04/07/2022
Tramadol-Like Agents PDL Edit (Annual)	04/07/2022
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit (Annual)	04/07/2022